David L. Tait

Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

David L. Tait, Patrice S. Obermiller, A R Hatmaker et al. · PubMed · 1999 · 72 citations

Immunology, Immunotherapy, Cancer Biology +16

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

David L. Tait, Patrice S. Obermiller, S Redlin-Frazier et al. · PubMed · 1997 · 66 citations

Gene Therapies, Cancer-associated Virus, Medicine +13

Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Julie Gottlieb Fisher, David L. Tait, Elizabeth Garrett‐Mayer et al. · Targeted Oncology · 2020 · 44 citations

Breast Oncology, Medicine, Pathology +8

When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer

Jubilee Brown, Lane Drury, Erin K. Crane et al. · Journal of Minimally Invasive Gynecology · 2018 · 42 citations

Laparoscopy, Surgical Oncology, Gynecologic Surgery +10

A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: A gynecologic oncology group study

David L. Tait, John A. Blessing, James Hoffman et al. · Gynecologic Oncology · 2010 · 41 citations

Medicine, Cancer Management, Gynecology +6